PATENT CLAIM ANALYSIS

Application Number: 15981008
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["424", "009100"]

Abstract:
The application identifies novel fragments of alpha-synuclein in patients with Lewy Body Disease (LBD) and transgenic animal models thereof. These diseases are characterized by aggregations of alpha-synuclein. The fragments have a truncated C-terminus relative to full-length alpha-synuclein. Some fragments are characterized by a molecular weight of about 12 kDa as determined by SDS gel electrophoresis in tricine buffer and a truncation of at least ten contiguous amino acids from the C-terminus of natural alpha-synuclein. The site of cleavage preferably occurs after residue 117 and before residue 126 of natural alpha-synuclein. The identification of these novel fragments of alpha-synuclein has a number of application in for example, drug discovery, diagnostics, therapeutics, and transgenic animals.

Claim (Index 41):
The antibody of  claim 36  designated 12C6 or 7G8.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 93.0
- Lexical Diversity: 1.58228
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11194115', '13604441', '10969335', '11842054', '11710248']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8260364995612269
- 35 USC 102 Novelty (BERT): 0.5933275230288386
- Combined Prediction Score: 0.8027656019079881
- Mean Citation Score: 540.5586099999998
- Max Citation Score: 644.30115
- Similarity Product: 416.4610394153237

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test